Analyst Reco. Immutep ADR Nasdaq

Equities

IMMP

US45257L1089

Market Closed - Nasdaq Other stock markets 21:00:00 27/06/2024 BST			5-day change	1st Jan Change
1.87 ^USD	-32.49%		-27.80%	-22.08%

06-27	ADRs End Flat; Alarum Technologies Climbs 26%	DJ
06-27	Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Baird Trims Immutep Price Target to $6 From $7, Maintains Outperform Rating	06-27	MT
Capital One Initiates Immutep at Overweight Rating With $10 Price Target	05-17	MT
Canaccord Starts Immutep at Buy, Price Target is AU$1.00	04-30	MT
Baird Initiates Immutep With Outperform Rating, $7 Price Target	03/08/23	MT
Maxim Group Adjusts Price Target on Immutep to $10 From $8, Keeps Buy Rating	18/05/23	MT
Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers	03/06/22	CI
AIPAC final data as expected: Phase III supported with maintaining a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)	12/11/21	PU
O/W: IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)	03/11/21	PU
Immutep : Ladenburg Thalman - New Age Immune Regulator; Initiate with a Buy Rating and $8.30 Price Target	03/08/21	PU
IMMUTEP : Ladenburg Thalmann Starts Immutep at Buy With $8.30 Price Target	03/08/21	MT
Immutep : Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Checkpoint - Transferring Coverage with a Buy Rating and $8 PT	16/07/21	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Securing my Investments

fermer